BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38402381)

  • 1. Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1.
    Cieza Rivera AM; Lobato Fuertes C; Fernández-Villa T; Martín Sánchez V; Atallah I
    Orphanet J Rare Dis; 2024 Feb; 19(1):85. PubMed ID: 38402381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement.
    Bottesi G; Spoto A; Trevisson E; Zuccarello D; Vidotto G; Cassina M; Clementi M
    Br J Dermatol; 2020 Jun; 182(6):1449-1457. PubMed ID: 31329288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and preliminary evaluation of the Neurofibromatosis Type 1 Adult Quality of Life (NF1-AdQoL) questionnaire.
    Crawford H; North K; Wilson MJ; Berman Y; McKelvey-Martin V; Morrison PJ; Fleming J; Barton B
    Clin Exp Dermatol; 2022 Feb; 47(2):271-281. PubMed ID: 34342021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
    Fertitta L; Bergqvist C; Armand ML; Moryousef S; Ferkal S; Jannic A; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1359-1366. PubMed ID: 35412677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.
    Ferner RE; Thomas M; Mercer G; Williams V; Leschziner GD; Afridi SK; Golding JF
    Health Qual Life Outcomes; 2017 Feb; 15(1):34. PubMed ID: 28193237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.
    Wolters PL; Burns KM; Martin S; Baldwin A; Dombi E; Toledo-Tamula MA; Dudley WN; Gillespie A; Widemann BC
    Am J Med Genet A; 2015 Sep; 167A(9):2103-13. PubMed ID: 25976979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
    Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
    Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of health concerns in people with neurofibromatosis type 1.
    Fleming J; Morgan O; Wong C; Schlub TE; Berman Y
    Mol Genet Genomic Med; 2023 Jan; 11(1):e2077. PubMed ID: 36444392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
    Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
    Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases.
    Page PZ; Page GP; Ecosse E; Korf BR; Leplege A; Wolkenstein P
    Am J Med Genet A; 2006 Sep; 140(18):1893-8. PubMed ID: 16906549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.
    Cohen JS; Levy HP; Sloan J; Dariotis J; Biesecker BB
    Clin Genet; 2015 Nov; 88(5):425-30. PubMed ID: 25534182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with neurofibromatosis 1 in Japan: A questionnaire survey using EQ-5D-5L.
    Yoshida Y; Ehara Y; Koga M; Imafuku S
    J Dermatol; 2022 Dec; 49(12):1228-1232. PubMed ID: 35781730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1.
    Graf A; Landolt MA; Mori AC; Boltshauser E
    J Pediatr; 2006 Sep; 149(3):348-53. PubMed ID: 16939745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in patients with neurofibromatosis type 1: a nationwide database study in Japan from 2015 to 2019.
    Yamauchi T; Suka M
    Environ Health Prev Med; 2023; 28():77. PubMed ID: 38057084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients.
    Kodra Y; Giustini S; Divona L; Porciello R; Calvieri S; Wolkenstein P; Taruscio D
    Dermatology; 2009; 218(3):215-20. PubMed ID: 19088462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior.
    Krab LC; Oostenbrink R; de Goede-Bolder A; Aarsen FK; Elgersma Y; Moll HA
    J Pediatr; 2009 Mar; 154(3):420-5, 425.e1. PubMed ID: 18950800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.
    Wolkenstein P; Rodriguez D; Ferkal S; Gravier H; Buret V; Algans N; Simeoni MC; Bastuji-Garin S
    Br J Dermatol; 2009 Apr; 160(4):844-8. PubMed ID: 19067713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity.
    Chernyshov PV
    G Ital Dermatol Venereol; 2016 Feb; 151(1):37-43. PubMed ID: 24927171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings.
    Młynek A; Magerl M; Hanna M; Lhachimi S; Baiardini I; Canonica GW; Brzoza Z; Kasperska-Zajac A; Rogala B; Zalewska-Janowska A; Zuberbier T; Maurer M
    Allergy; 2009 Jun; 64(6):927-36. PubMed ID: 19453340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.